分类： 其他平台
2013-10-09 15:21:01
Furthermore, DISH Networks made acounterbid for Clearwire totaling $3.30 per share and offering $2.2 billion for 24% of Clearwire's spectrum holdings, which could sway Clearwire completely away from Sprint or force Sprint to spend even more on acquiring a cashburning business. Conceptually, targeting inhibition of this protein thought to be vital to cancer cell growth should result in cancer cell death. While that sounds great on paper, we're in about the third inning of a nineinning game, and retaspimycin (formerly IPI504) is only in midstage trials for the treatment of nonsmallcell lung cancer, yet investors have priced Infinity as if approval is a certainty and we're on track to hit peak sales of the drug.
Beyond retaspimycin, Infinity has three ongoing trials for its PI3K inhibitor program, covering asthma, rheumatoid arthritis, and bloodborne malignancies, but only one has even reached midstage trials. In Infinity's most recent quarterly update, we learned that the company does have ample cash to conduct its trials well into 2015, but we're also staring down cash burn of $115 million to $125 million this year.
Add to My Watchlist.
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brandnew free report: "." I invite you to take a copy, free for a limited time. Just to access the report and find out the name of this undertheradar company.
Fool contributorSean Williamshas no material interest in any companies mentioned in this article. He's a total nerd when it comes to making lists. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
3 players leave JMU
